Impact of Measurable Residual Disease Clearance Kinetics in Patients with AML Undergoing Intensive Chemotherapy.
Jen WY, Sasaki K, Ravandi F, Kadia TM, Wang SA, Wang W, Loghavi S, Daver NG, DiNardo CD, Issa GC, Abbas HA, Nasnas C, Bataller A, Urrutia S, Karrar OS, Pierce SA, Kantarjian HM, Short NJ.
Jen WY, et al. Among authors: wang sa.
Blood Adv. 2024 Dec 4:bloodadvances.2024013826. doi: 10.1182/bloodadvances.2024013826. Online ahead of print.
Blood Adv. 2024.
PMID: 39631072